ACADIA Pharmaceuticals Inc.
ACAD
$25.13
-$0.32-1.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.41% | 22.42% | 31.85% | 47.06% | 61.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.41% | 22.42% | 31.85% | 47.06% | 61.65% |
| Cost of Revenue | -6.46% | -0.98% | -2.08% | -10.24% | 45.08% |
| Gross Profit | 34.19% | 45.61% | 71.89% | 137.46% | 81.27% |
| SG&A Expenses | 17.02% | 19.02% | 16.47% | 13.87% | 14.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.30% | 9.12% | 7.35% | 2.01% | 27.91% |
| Operating Income | 361.08% | 2,352.10% | 235.16% | 182.35% | 117.90% |
| Income Before Tax | 485.61% | 1,676.93% | 605.67% | 203.85% | 143.20% |
| Income Tax Expenses | 201.21% | 116.49% | 208.53% | -52.34% | 208.89% |
| Earnings from Continuing Operations | 626.84% | 13,484.97% | 469.50% | 186.36% | 127.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 626.84% | 13,484.97% | 469.50% | 186.36% | 127.58% |
| EBIT | 361.08% | 2,352.10% | 235.16% | 182.35% | 117.90% |
| EBITDA | 246.81% | 1,820.66% | 269.64% | 192.97% | 127.58% |
| EPS Basic | 627.33% | 11,962.07% | 461.27% | 185.19% | 126.81% |
| Normalized Basic EPS | 234.01% | 1,262.50% | 320.83% | 206.73% | 136.22% |
| EPS Diluted | 660.79% | 7,291.58% | 448.69% | 183.42% | 125.14% |
| Normalized Diluted EPS | 239.40% | 1,361.70% | 318.28% | 206.07% | 135.50% |
| Average Basic Shares Outstanding | 1.18% | 1.15% | 1.24% | 1.41% | 1.51% |
| Average Diluted Shares Outstanding | 0.86% | 0.65% | 1.16% | 1.83% | 1.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |